


SOHM, Inc. secures key patent in Japan for revolutionary gene editing technology

27 November 2024 | News

Paving way for genetic disorder treatment breakthroughs in India



SOHM, Inc., a globally recognised pharmaceutical company focused on developing, manufacturing and distributing Generic, Branded Generic, Private label, and Sohm-innovated Pharmaceuticals, Cosmeceuticals and Nutraceutical products, has announced the approval of a critical patent by the Japan Patent Office (JPO).

This patent safeguards Indian firm SOHM's pioneering ABBIE (A Base Binding Integrase Enzyme) genome editing technology, a development poised to significantly impact India's rapidly evolving biotechnology landscape.

The ABBIE technology represents a substantial advancement in gene editing, offering unprecedented precision and safety that could transform treatment approaches for a range of genetic disorders. As India grapples with a considerable burden of genetic diseases, including sickle cell anaemia, thalassemia, and various forms of genetic cancers, the implementation of this innovative technology stands to provide significant therapeutic advancements for millions of individuals affected by these conditions.

India, home to a significant portion of the global disease burden, particularly genetic disorders, stands to benefit immensely from advancements in gene editing technology. Millions of Indians suffer from conditions like sickle cell anaemia, thalassemia, and various genetic cancers. For instance, it is estimated that over 100,000 children are born with thalassemia major in India each year.

India's burgeoning biotechnology sector, coupled with increasing government investments and a growing pool of skilled scientists, provides a fertile ground for the application of advanced technologies like gene editing. By fostering collaborations between Indian and international researchers, SOHM aims to accelerate the development of innovative therapies and improve the lives of millions of people.

SOHM's ABBIE technology avoids risks by using a unique approach that doesn't require creating double-stranded DNA breaks. This makes the process more efficient and safe therebyreducing the chances of off-target effects. SOHM's ABBIE technology can also deliver significantly larger amounts of genetic information. This technology offers a significant advancement in gene editing, providing highly targeted modifications with minimal unintended changes, reduced risk of

harmful genetic alterations, and rapid, efficient gene modification. Moreover, the advantages presented will significantly lower the cost of future therapies allowing for increased access to a greater population of patients.	r